[PDF][PDF] Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French …
N Boissel, O Nibourel, A Renneville… - Journal of Clinical …, 2010 - researchgate.net
N Boissel, O Nibourel, A Renneville, C Gardin, O Reman, N Contentin, D Bordessoule…
Journal of Clinical Oncology, 2010•researchgate.netPurpose Recently, whole-genome sequencing in acute myeloid leukemia (AML) identified
recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations (IDH1m), previously
reported to be involved in gliomas as well as IDH2 mutations (IDH2m). The prognosis of
both IDH1m and IDH2m in AML remains unclear.
recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations (IDH1m), previously
reported to be involved in gliomas as well as IDH2 mutations (IDH2m). The prognosis of
both IDH1m and IDH2m in AML remains unclear.
Purpose
Recently, whole-genome sequencing in acute myeloid leukemia (AML) identified recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations (IDH1m), previously reported to be involved in gliomas as well as IDH2 mutations (IDH2m). The prognosis of both IDH1m and IDH2m in AML remains unclear.
researchgate.net
